Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Study of AGS‑004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Argos Therapeutics
ClinicalTrials.gov Identifier:
NCT00672191
First received: May 5, 2008
Last updated: January 22, 2013
Last verified: January 2013

May 5, 2008
January 22, 2013
February 2008
August 2010   (final data collection date for primary outcome measure)
Ability of AGS-004 therapy to improve immune control of HIV-1 replication [ Time Frame: Study Week 26 through end of study ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00672191 on ClinicalTrials.gov Archive Site
  • Change in plasma HIV-1 RNA set point [ Time Frame: Study Week 26 through end of study ] [ Designated as safety issue: No ]
  • T cell responses to AGS-004 therapy and exploratory studies to investigate the mechanism of action of AGS-004. [ Time Frame: Study Week 26 through end of study ] [ Designated as safety issue: No ]
  • Safety and tolerability of AGS-004 [ Time Frame: Study Week 26 through end of study ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Phase II Study of AGS‑004 as an Immunotherapeutic in Antiretroviral Therapy (ART)-Treated Subjects Infected With HIV
A Phase II Study Testing the Activity and Safety of AGS-004 as an Immunotherapeutic in Successfully ART-Treated Subjects Infected With HIV-1 in Combination With ART Followed by ART Interruption

The purpose of this study is to examine the ability of AGS-004 to control HIV-1 replication and to determine if HIV-1 immunotherapy made with dendritic cells is safe and well tolerated, to determine if immunotherapy increases the body's immune response to HIV-1; and, to determine if after stopping anti-HIV drugs, immunotherapy can control the HIV-1 virus.

Although chronic ART raises cluster of differentiation CD 4+ T cell counts and improves immune function, the immune systems' ability to control HIV-1 replication is not improved. AGS-004 is an immunotherapeutic agent made from autologous DCs co electroporated with amplified in vitro transcribed (IVT) ribonucleic acid (RNA) encoding CD40L and with IVT RNA encoding three or four autologous HIV-1 antigens. The HIV-1 RNA is derived from the plasma sample taken immediately prior to the initiation of ART.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
HIV Infections
Biological: AGS-004
HIV-1 Immune Therapy
Experimental: 1
Intervention: Biological: AGS-004
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
59
November 2011
August 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18 to 60 years of age
  • HIV-1 infection
  • Subjects must be on their first ART regimen for at least 3 months: 2 NRTIs together with an NNRTI and/or at least 1 PI (prior changes to ART regimen are allowed if due to tolerability, guideline change, or to simply dosing but not for viral control)
  • Durable viral suppression (below limit of detection) for at least 3 months prior ot Screening
  • CD4+ T cell count ≥ 450 cells/mm3 for at least 90 days immediately prior to Screening
  • Availability of ≥ 1.2 mL of continually frozen plasma (may have been thawed and refrozen only once) drawn no more than 90 days before starting ART and preferably within 30 days.
  • Pre-ART plasma HIV-1 RNA levels of ≥ 15,000 copies/mL at the time the plasma was archived before commencing ART
  • Pre-ART nadir CD4+ T cell count ≥ 200 cells/mm3 (cell count of < 200 cells/mm3 on one occasion is allowed if subsequent pre-ART CD4+ cell counts were > 200 cells/mm3 on at least two time points.
  • Laboratory values obtained at Screening and confirmed just prior to Baseline Day 1:

    • Creatinine ≤ 1.5 x upper limit of normal (ULN);
    • AST (SGOT), ALT (SG`PT), and alkaline phosphatase ≤ 3 x ULN;
    • ANC ≥ 750 cells/mm3;
    • Hemoglobin ≥ 10 g/dL; and,
    • Platelet count ≥ 75,000/mm3
  • Female subjects of reproductive potential must have a negative serum or urine pregnancy test with a sensitivity of at most 50 mIU/mL performed within 30 days prior to Screening.
  • All subjects must agree not to participate in a conception process and use contraception.
  • Ability to communicate effectively with study personnel; considered reliable, willing, and cooperative in terms of compliance with the Protocol requirements.
  • Voluntary informed consent given to participate in the study.
  • Successful RNA amplification of at least 3 antigens (must include Gag).

Exclusion Criteria:

  • HIV-2 antibody positive.
  • Positive test for other infectious diseases including:

    • clinically active, untreated syphilis (positive rapid plasma regain test (RPR)
    • clinically active hepatitis B infection (positive Hep B surface antigen HBsAg)
    • active hepatitis C infection or any history of hepatitis C infection
    • positive test for HTLV Type I or Type II antibody
  • Any acute infection or serious medical illness within 14 days prior to study entry
  • History of lymph node irradiation or dissection
  • Pregnancy or breast-feeding
  • Previous use of any HIV-1 immunotherapy, including IL-2
  • Use of hydroxyurea within 30 days prior to Screening
  • Immunodeficiency other than HIV-1 or requirements to take immuno-modulating concomitant medications
  • Known allergy or sensitivity to the investigational immunotherapy or its formulation
  • Use of systemic corticosteroids and use of topical steroids over a total area exceeding 15 cm2 within 4 weeks of Screening or anticipated need for periodic use of corticosteroids during the study
  • Receipt of any immune modulators or suppressors within 30 days of Screening
  • Active autoimmune disease such as:

    • Rheumatoid arthritis
    • Inflammatory bowel disease
    • Systemic lupus erythematosis
    • Ankylosing spondylitis
    • Hashimoto's disease
    • Scleroderma
    • Multiple sclerosis
    • Autoimmune hemolytic anemia
    • Immune thrombocytopenic purpura
  • Type I diabetes mellitus (insulin therapy for Type II diabetes is permitted)
  • Participation in another clinical trial within 30 days of Screening or use of investigational agents (previous use of expanded access ARTs is permitted)
  • Body weight less than 30 kg.
  • Changes in ART regimen due to virologic failure (not including toxicities)
  • Presence of factors predicting insufficient adherence to the protocol.
  • Any condition that in the assessment of the investigator would indicate that it is not in the best interest of the subject or incompatible with the any aspect of the study design, treatment plan, and study objectives for a subject to participate.
  • History or other evidence of severe illness, malignancy, or any other condition that would make the subject, in the opinion of the investigator, unsuitable for the study.
Both
18 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Canada
 
NCT00672191
AGS-004-001
Yes
Argos Therapeutics
Argos Therapeutics
Not Provided
Principal Investigator: Jean-Pierre Routy, MD McGill University Health Center
Principal Investigator: Mona Loutfy, MD Maple Leaf Clinic
Principal Investigator: Cecile Tremblay, MD CHUM- Hotel Dieu de Montreal
Principal Investigator: John Gill, MD Southern Alberta Clinic
Principal Investigator: Jean-Guy Baril, MD Clinque Medical du Quartier Latin
Principal Investigator: Sylvie Vezina, MD Clinque medicale l'Actuel
Principal Investigator: Jonathan B Angel, MD The Ottawa Hospital
Principal Investigator: Sharon Walmsley, MD UHN
Principal Investigator: Fiona Smaill, MD Hamilton Health Sciences Corporation
Principal Investigator: Anita Rachlis, MD Sunnybrook Health Sciences Center
Principal Investigator: Julio Montaner, MD Providence Health Care Society
Principal Investigator: Jeffrey Jacobson, MD Partnership Comprehensive Care Practice
Argos Therapeutics
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP